The structure of the proteinaceous inhibitor PliI from Aeromonas hydrophila in complex with its target lysozyme by Leysen, Seppe et al.
electronic reprint
Acta Crystallographica Section D
Biological
Crystallography
ISSN 1399-0047
The structure of the proteinaceous inhibitor PliI from
Aeromonas hydrophila in complex with its target lysozyme
Seppe Leysen, Joris M. Van Herreweghe, Kazunari Yoneda, Makoto Ogata,
Taichi Usui, Tomohiro Araki, Christiaan W. Michiels and Sergei V. Strelkov
Acta Cryst. (2015). D71, 344–351
Copyright c© International Union of Crystallography
Author(s) of this paper may load this reprint on their own web site or institutional repository provided that
this cover page is retained. Republication of this article or its storage in electronic databases other than as
specified above is not permitted without prior permission in writing from the IUCr.
For further information see http://journals.iucr.org/services/authorrights.html
Acta Crystallographica Section D: Biological Crystallography welcomes the submission of
papers covering any aspect of structural biology, with a particular emphasis on the struc-
tures of biological macromolecules and the methods used to determine them. Reports
on new protein structures are particularly encouraged, as are structure–function papers
that could include crystallographic binding studies, or structural analysis of mutants or
other modified forms of a known protein structure. The key criterion is that such papers
should present new insights into biology, chemistry or structure. Papers on crystallo-
graphic methods should be oriented towards biological crystallography, and may include
new approaches to any aspect of structure determination or analysis. Papers on the crys-
tallization of biological molecules will be accepted providing that these focus on new
methods or other features that are of general importance or applicability.
Crystallography Journals Online is available from journals.iucr.org
Acta Cryst. (2015). D71, 344–351 Leysen et al. · PliI
research papers
344 doi:10.1107/S1399004714025863 Acta Cryst. (2015). D71, 344–351
Acta Crystallographica Section D
Biological
Crystallography
ISSN 1399-0047
The structure of the proteinaceous inhibitor PliI
from Aeromonas hydrophila in complex with its
target lysozyme
Seppe Leysen,a‡ Joris M. Van
Herreweghe,b Kazunari Yoneda,c
Makoto Ogata,d Taichi Usui,e
Tomohiro Araki,c Christiaan W.
Michielsb and Sergei V.
Strelkova*
aLaboratory for Biocrystallography, Department
of Pharmaceutical and Pharmacological
Sciences, KU Leuven, 3000 Leuven, Belgium,
bLaboratory of Food Microbiology, Leuven
Food Science and Nutrition Research Centre,
KU Leuven, 3000 Leuven, Belgium,
cDepartment of Bioscience, School of
Agriculture, Tokai University, Kawayo,
Minamiaso, Kumamoto 869-1404, Japan,
dDepartment of Chemistry and Biochemistry,
Fukushima National College of Technology,
30 Nagao, Kamiarakawa, Taira, Iwaki,
Fukushima 970-8034, Japan, and eDepartment
of Bioscience, Graduate School of Science and
Technology, Shizuoka University, 836 Ohya,
Suruga, Shizuoka 422-8529, Japan
‡ Current address: Technische Universiteit
Eindhoven, The Netherlands.
Correspondence e-mail:
sergei.strelkov@pharm.kuleuven.be
# 2015 International Union of Crystallography
Recent microbiological data have revealed that Gram-
negative bacteria are able to protect themselves against the
lytic action of host lysozymes by secreting proteinaceous
inhibitors. Four distinct classes of such inhibitors have been
discovered that specifically act against c-type, g-type and
i-type lysozymes. Here, the 1.24 A˚ resolution crystal structure
of the periplasmic i-type lysozyme inhibitor from Aeromonas
hydrophila (PliI-Ah) in complex with the i-type lysozyme from
Meretrix lusoria is reported. The structure is the first to explain
the inhibitory mechanism of the PliI family at the atomic level.
A distinct ‘ridge’ formed by three exposed PliI loops inserts
into the substrate-binding groove of the lysozyme, resulting
in a complementary ‘key–lock’ interface. The interface is
principally stabilized by the interactions made by the PliI-Ah
residues Ser104 and Tyr107 belonging to the conserved SGxY
motif, as well as by the other conserved residues Ser46 and
Asp76. The functional importance of these residues is
confirmed by inhibition assays with the corresponding point
mutants of PliI-Ah. The accumulated structural data on
lysozyme–inhibitor complexes from several classes indicate
that in all cases an extensive interface of either a single or a
double ‘key–lock’ type is formed, resulting in highly efficient
inhibition. These data provide a basis for the rational
development of a new class of antibacterial drugs.
Received 2 July 2014
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PDB reference: PliI–lysozyme
complex, 4pj2
1. Introduction
In the animal kingdom, lysozymes are important enzymes
of the innate immune system. Three major types of animal
lysozymes can be discriminated based on their primary
sequences. They are designated as c-type (chicken or common
type), g-type (goose type) and i-type (invertebrate type). The
lysozymes exert a strong antibacterial activity by undermining
the structural integrity of the bacterial cell wall, ultimately
leading to osmotic lysis. In particular, they catalyse hydrolysis
of the (1–4) glycosidic bond between N-acetylmuramic acid
(NAM) and N-acetylglucosamine (NAG), which are the
disaccharide building blocks of the peptidoglycan layer of the
cell wall. In their substrate-binding cleft, lysozymes have six
subsites for binding NAG and/or NAM molecules. These
subsites are labelled A–F for c-type and i-type lysozymes and
B–G for g-type lysozymes. Peptidoglycan cleavage ultimately
occurs between the NAM and NAG molecules occupying
subsites D and E (see, for example, Callewaert & Michiels,
2010; Van Herreweghe & Michiels, 2012).
From their side, bacteria have developed strategies to
protect their peptidoglycan layer against the lytic action of
their host’s lysozymes. A well known strategy is the intro-
duction of chemical modifications into the peptidoglycan
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backbone (reviewed in Davis & Weiser, 2011), while a more
recently discovered strategy is the production of protein-
aceous lysozyme inhibitors. To date, four distinct lysozyme
inhibitor families have been described (reviewed in Call-
ewaert et al., 2012). Initially the Ivy (inhibitor of vertebrate
lysozyme) family was identified (Monchois et al., 2001), and
was soon followed by three other lysozyme inhibitor families
designated MliC/PliC (membrane-associated/periplasmic
lysozyme inhibitor of c-type lysozyme), PliG (periplasmic
lysozyme inhibitor of g-type lysozyme) and PliI (periplasmic
lysozyme inhibitor of i-type lysozyme) (Callewaert et al., 2008;
Van Herreweghe et al., 2010; Vanderkelen et al., 2011).
In the past, X-ray structure determination of the complexes
formed by Ivy, MliC/PliC and PliG with their respective
lysozymes has helped to explain their inhibitory mechanisms
(Leysen et al., 2013; Yum et al., 2009; Abergel et al., 2007; Um
et al., 2013). Recently, we have also determined the crystal
structure of PliI from Aeromonas hydrophila (PliI-Ah) and
explored its inhibitory action on the i-type lysozyme from
the clam Venerupis philippinarum (formerly known as Tapes
japonica; Vp-iLys; Leysen et al., 2011). Here, we describe the
crystallographic complex of PliI-Ah with the i-type lysozyme
from the closely related clam Meretrix lusoria (Ml-iLys). This
structure is the first to explain the inhibitory mechanism of the
PliI family at the atomic level.
2. Materials and methods
2.1. Protein purification
A pET-26b(+)-based construct expressing the PliI-Ah gene
(Van Herreweghe et al., 2010) was introduced into Escherichia
coli BL21(DE3) cells by heat-shock transformation. A single
colony was used to inoculate 1 ml LB containing 100 mg ml1
ampicillin. After 8 h incubation at 37C, 500 ml of this pre-
culture was used to inoculate 1 l ZYP-5052 auto-induction
medium (Studier, 2005) containing 100 mg ml1 ampicillin and
0.1%(v/v) antifoam SE-15 (Sigma–Aldrich). The culture was
grown at 24C until it reached an OD600 nm of 4.0. At this
point, the temperature was decreased to 18C and the culture
was allowed to grow for an additional 24 h. The cells were
pelleted by centrifugation, resuspended in 50 mM sodium
phosphate, 250 mM NaCl, 12.5 mM imidazole pH 7.5
(IMAC12.5 buffer) and lysed using an EmulsiFlex-C5 homo-
genizer (Avestin) followed by sonication for 4 min with 60%
amplitude and 1 s on/off pulses. The lysate was clarified by
centrifugation. The supernatant containing PliI-Ah with a
vector-encoded C-terminal Leu-Glu-(His)6 tag was loaded
onto a 3 ml nickel-chelating column (His60 Ni Superflow
resin, Clontech) equilibrated with IMAC12.5 buffer. The
column was washed with three column volumes of this buffer
containing 0.1%(v/v) Triton X-100 followed by a further three
column volumes of the buffer without detergent. PliI-Ah was
eluted from the column with ten column volumes of 50 mM
sodium phosphate, 250 mM NaCl, 250 mM imidazole pH 7.5
while collecting 1 ml fractions. The fractions containing PliI-
Ah were combined and dialysed overnight at 4C against
20 mM bis-tris pH 7.0, 10%(w/v) glycerol. Next, PliI-Ah was
loaded onto a HiTrap Q HP column (GE Healthcare) equili-
brated with 20 mM bis-tris pH 7.0 and a linear gradient of
0–400 mM NaCl (0–40% of a buffer consisting of 20 mM bis-
tris pH 7.0, 1M NaCl) was applied over 20 column volumes.
Fractions containing PliI-Ah were pooled and concentrated
using an Amicon ultracentrifugation device with a 3 kDa
cutoff (Millipore). Finally, PliI-Ah was further purified by size-
exclusion chromatography on a Superdex 75 pg 16/60 column
(GE Healthcare) equilibrated with 10 mM Tris–HCl, 0.5 mM
EDTA, 250 mM KCl pH 7.5 (SEC buffer).
Ml-iLys (an isoform with a Thr residue at position 5) was
purified from clams as described in Kuwano, Yoneda, Kawa-
guchi, Araki et al. (2013). The purification of Vp-iLys was
performed as described in Van Herreweghe et al. (2010).
2.2. Crystallographic analysis
The PliI-Ah–Ml-iLys complex was formed by mixing the
proteins in equimolar amounts in SEC buffer. The complex
was concentrated to 9.5 mg ml1 using an Amicon ultra-
centrifugation device with a 3 kDa cutoff (Millipore). The
protein concentration was determined by measuring the
absorbance at 280 nm. To screen for crystallization conditions,
the commercially available Index (Hampton Research) and
PACT (Qiagen) kits were used. Trials were set up using the
sitting-drop technique in MRC-type 96-well crystallization
plates (Molecular Dimensions). For each condition, 100 nl
protein-complex solution was mixed with an equal amount of
precipitant solution. The best crystals were obtained after 3 d
at 20C with 0.1M dl-malic acid/MES/Tris base cocktail
buffer (MMT buffer as described in the Qiagen protocol),
25%(w/v) PEG 1500. A crystal measuring roughly 60  70 
30 mm was transferred to precipitant solution supplemented
with 20% glycerol and flash-cooled in liquid nitrogen.
Diffraction data were collected at 100 K on the PROXIMA1
beamline at the SOLEIL synchrotron, France. The data sets
were indexed and integrated using XDS (Kabsch, 2010) and
scaled using SCALA (Evans, 2006). The structure was phased
by molecular replacement in Phaser (McCoy et al., 2007) using
the structures of Ml-iLys (PDB entry 3ab6; Kuwano, Yoneda,
Kawaguchi & Araki, 2013) and PliI-Ah (PDB entry 3od9;
Leysen et al., 2011) as search models. Iterative rounds of
manual building using Coot (Emsley & Cowtan, 2004) and
refinement employing the PHENIX package (Adams et al.,
2010) were used to complete the atomic model. The final
atomic coordinates and the experimental structure factors
were deposited in the Protein Data Bank under accession code
4pj2. Analysis of the PliI-Ah–Ml-iLys complex interface was
performed using the PISA web server (Krissinel & Henrick,
2007).
2.3. Assays with designed PliI-Ah mutants
Generation of the PliI-Ah S104A/Y107A double mutant
has been described previously (Leysen et al., 2011). Using the
same procedure, alanine substitutions were introduced to
create the mutants S46A, D76A, S46A/S104A/Y107A, D76A/
S104A/Y107A and S46A/D76A/S104A/Y107A. The primer
research papers
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sequences were S46A-Fw (forward), GGCGAACCTGCC-
GCCACCGGCAGCTACG, S46A-Rv (reverse), GCGCCCT-
CTGCTGACGGTCACTACCTGGCCTGAGG, D76A-Fw,
GTGCTGCCGCGCGCTGGCAGCATCAAGG, and D76A-
Rv, CTTGCCGTCGATGAACTGATCCAGCGGGAACTG-
GGGGTT. Vp-iLys lytic activity and the inhibition of this
activity by wild-type and mutant PliI-Ah were measured as
described previously (Van Herreweghe et al., 2010). Briefly,
lyophilized Micrococcus luteus cells (Sigma–Aldrich) were
resuspended at 0.8 mg ml1 in 10 mM potassium phosphate
buffer pH 7.0. Thereafter, the cell lysis induced by the addition
of Vp-iLys alone or together with a PliI-Ah variant was
monitored at 30C using a Bioscreen C Microbiology Reader
(Labsystems Oy, Helsinki, Finland). The efficiency of inhibi-
tion was calculated as I = [(L0  L)  (R0  R)]/[(L0  L) 
(B0  B)], where L0  L is the decrease in the OD600 nm
reading over 2 h upon the addition of lysozyme alone, R0  R
is the equivalent decrease upon the addition of both lysozyme
and the inhibitor and B0  B is the decrease after the addition
of buffer only. The amount of added lysozyme was
0.55 mg ml1 such that the OD600 nm decrease with lysozyme
alone was 0.5 in 2 h. The amount of the inhibitor was
adjusted such that the inhibition efficiency was 50%. The
relative activity of each mutant was then calculated as the
ratio of the concentration-normalized inhibition efficiencies of
the mutant and wild-type PliI-Ah.
3. Results and discussion
3.1. Crystal structure determination of the PliI-Ah–MI-iLys
complex
We have recently reported that PliI-Ah forms a very tight
complex with an i-type lysozyme from V. philippinarium (Vp-
iLys). Using surface plasmon resonance (SPR), this inter-
action was found to have a Kd of 47 pM (Leysen et al., 2011).
For these experiments, Vp-iLys was produced recombinantly
in Pichia pastoris, but the small yields were insufficient for
crystallographic studies. Here, we have used a closely related
i-type lysozyme from another clam, M. lusoria (Ml-iLys), that
can be readily purified directly from the animal tissue in
milligram amounts (Kuwano, Yoneda, Kawaguchi, Araki et al.,
2013). Ml-iLys and Vp-iLys share 65% amino-acid identity
(Kuwano, Yoneda, Kawaguchi, Araki et al., 2013). In line with
this, their atomic structures are readily superimposable,
yielding a root-mean-square deviation (r.m.s.d.) of 0.59 A˚ over
122 C atom pairs (Kuwano, Yoneda, Kawaguchi & Araki,
2013).
The complex of recombinantly produced PliI-Ah and
tissue-purified Ml-iLys could be readily formed upon mixing
the proteins in equimolar amounts and successfully crystal-
lized. The structure has been determined to 1.24 A˚ resolution
(Table 1). This surpasses the diffraction quality of both PliI-
Ah (Leysen et al., 2011; PDB entry 3od9, resolution 1.41 A˚)
and Ml-iLys (Kuwano, Yoneda, Kawaguchi & Araki, 2013;
PDB entry 3ab6, resolution 1.78 A˚) alone. Moreover, such
diffraction quality is outstanding for a protein–protein
complex. An automated search of the PDB indicates that
there are only 164 entries (0.17% of the PDB) resolved at
1.24 A˚ resolution or better and containing more than one
distinct polypeptide chain in the asymmetric unit. Manual
examination of these entries reveals that the majority of them
are protein–peptide complexes, with only a few being true
protein–protein complexes, including the complex of PliG-Ec
with Atlantic salmon g-type lysozyme at 0.95 A˚ resolution
(Leysen et al., 2013; Yum et al., 2009). The high quality of the
Ml-iLys–PliI-Ah complex crystals may reflect the compact,
highly ordered structure of either component as well as their
tight interaction.
3.2. Molecular basis of the inhibition of MI-iLys by PliI-Ah
There is one PliI-Ah dimer binding two Ml-iLys molecules
per asymmetric unit of the crystals, resulting in an arrange-
ment with twofold noncrystallographic symmetry (Fig. 1a).
Each MI-iLys molecule makes contacts with both chains of the
research papers
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Table 1
Crystallographic statistics.
Values in parentheses are for the highest resolution shell.
PDB code 4pj2
Data collection
Wavelength (A˚) 0.9791
Resolution range (A˚) 66–1.24 (1.31–1.24)
Space group P21
Unit-cell parameters (A˚, ) a = 132.2, b = 77.7, c = 42.9,
 = 108.1
Solvent content (%) 49
CC1/2† 0.999 (0.619)
Rmerge‡ 0.050 (0.839)
Rmeas§ 0.057 (0.958)
hI/(I)i 10.8 (1.7)
Completeness (%) 95.7 (89.8)
No. of unique reflections 144072
Multiplicity 4.3 (4.2)
Wilson B factor (A˚2) 15.6
Refinement
Resolution range used (A˚) 47.8–1.24
Total No. of reflections used 144031
No. of reflections in the ‘free’ set 1457
No. of non-H protein solvent atoms 3874/560
Rwork 0.148
Rfree 0.168
CCwork} 0.966
CCfree} 0.966
R.m.s. deviations from ideal values††
Bond lengths (A˚) 0.008
Bond angles () 1.2
Average B factor (A˚2)
Protein 20.8
Solvent 33.8
Ramachandran plot‡‡
Favoured (%) 98.6
Outliers (%) 0
MolProbity score/percentile‡‡ 1.35/88
Clashscore/percentile‡‡ 3.74/91
Good rotamers‡‡ (%) 98.2
† CC1/2 is Pearson’s intra-data-set correlation coefficient as described in Karplus &
Diederichs (2012). ‡ Rmerge =
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ, where
Ii(hkl) is the intensity of the ith observation of reflection hkl and hI(hkl)i is the
average intensity of reflection hkl. § Rmeas =
P
hklfNðhklÞ=½NðhklÞ  1g1=2P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ, where N(hkl) is the number of observations of
reflection hkl. } Correlation of experimental intensities with intensities calculated
from the refined model as described in Karplus & Diederichs (2012) †† As described in
Engh & Huber (1991). ‡‡ As calculated using MolProbity (Chen et al., 2010).
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PliI-Ah dimer, but the contact with one of the chains is more
extensive. The larger contact, referred to here as the ‘primary
interface’, essentially includes PliI-Ah loops 2, 4 and 6. In
addition, a smaller ‘secondary interface’ involves loop 3 of the
research papers
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Figure 1
The PliI-Ah–Ml-iLys complex. (a) Asymmetric unit of the crystals containing the PliI-Ah dimer (blue) and two lysozyme molecules (green). The PliI-Ah
residues involved in the primary interface (shown in red) are predominantly situated in loops 2, 4 and 6. The residues involved in the secondary interface
(shown in yellow) are in loop 3. (b) A close-up of the active site of MI-iLys in two superimposed structures: in complex with PliI-Ah (lysozyme shown in
green) and in complex with the substrate-like inhibitor 2,3-dideoxy-N,N0,N0 0,N0 0 0-tetraacetylchitotetraose-1,5-lactone (PDB entry 3ayq; inhibitor in
orange, lysozyme in grey). Loops 2, 4 and 6 occupy the substrate-binding groove, with the side chains of residues Ser46 and Ser104 matching the hydroxyl
moieties of the substrate-like inhibitor. (c, d) Close-up view of the primary PliI-Ah–Ml-iLys interface shown in two different orientations. Key
interactions are shown as dashed lines.
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other PliI-Ah chain in the dimer (Fig. 1a). The primary and
secondary interfaces measure about 730 and 240 A˚2, respec-
tively. Here, the calculated values were rounded up to 10 A˚2
to reflect the practically achievable precision (Novotny et al.,
2007). The total interface area (970 A˚2) is comparable to that
found in the lysozyme complexes of E. coli PliG (1200 A˚2),
Pseudomonas aeruginosaMliC (960 A˚2) and P. aeruginosa Ivy
(940 A˚2) (Abergel et al., 2007; Leysen et al., 2013; Yum et al.,
2009). It should also be noted that Ml-iLys–PliI-Ah complex
formation buries substantial fractions (15 and 14%) of the
solvent-accessible surfaces of the lysozyme and the inhibitor,
respectively.
The main contribution to the primary interface is owing to
PliI-Ah loop 6 (residues 101–107), which inserts into the active
site of the lysozyme, in line with our earlier hypothesis
(Leysen et al., 2011). This loop contains the GSGxY sequence
that is highly conserved across PliI molecules from various
bacterial species (Fig. 2). An SGxY motif is also found in the
PliG family members, whereas a closely related SGxxY motif
is present in the PliC/MliC family (Callewaert et al., 2012). The
detailed conformation of loop 6 together with the supporting
electron density is given in Supplementary Fig. S1. The
binding of loop 6 is responsible for 48% of the total area
buried upon complex formation. In addition, loops 2 and 4 are
also involved. Together, the three loops
form a ‘ridge’ that inserts into the
substrate-binding groove of the lyso-
zyme (Fig. 1d). The specific interactions
at the primary interface include 11
hydrogen bonds and a salt bridge
(Table 2). Here, it is most illustrative
to superimpose one Ml-iLys–PliI-Ah
complex onto the recently determined
structure of Ml-iLys in complex with
the substrate analogue 2,3-dideoxy-
N,N0,N00,N000-tetraacetylchitotetraose-1,5-
lactone (PDB entry 3ayq; K. Yoneda, Y.
Kuwano, T. Usui, M. Ogata, A. Suzuki
& T. Araki, unpublished work). The
latter contains four consecutive glucose-
based moieties that occupy substrate
subsites A–D in the groove. Compar-
ison of the structures readily reveals
that PliI loops 2, 4 and 6 block these
four subsites (Fig. 1b). Moreover,
PliI-Ah residues Ser46 (loop 2) and
Ser104 (loop 6) directly contribute to
mimicking the substrate, as their
hydroxyl side groups match the C6-
bound hydroxyls of sugar moieties in
subsites B and D, respectively (Fig. 1b).
Atomic coordinate superpositions
with the component structures reveal
that Ml-iLys–PliI-Ah complex forma-
tion does not change the overall
conformation of either protein
(Supplementary Fig. S2). Indeed, a
substrate-bound Ml-iLys structure (PDB entry 3ab6; Kuwano
et al., 2013) can be aligned with that in our complex with a C
r.m.s.d. of0.4 A˚ (0.46 and 0.29 A˚ for the two lysozyme copies
in the complex, respectively) over 118 aligned residues
(defined as residues deviating by less than 2 A˚ upon super-
position as calculated with the MatchMaker tool in Chimera;
Pettersen et al., 2004). Unbound PliI-Ah (PDB entry 3od9;
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Figure 2
Multiple sequence alignment of the PliI family. The following species abbreviations are used: Ah,
A. hydrophila; Ha, Herminiimonas arsenicoxydans; J, Janthinobacterium sp. Marseille; Lh,
Laribacter hongkongensis; B, Burkholderia sp. 383; Yp, Yersinia pestis; Re, Ralstonia eutropha.
Secondary-structure elements of PliI-Ah are indicated above the alignment. Loop 6 containing the
conserved motif SGxY is boxed. PliI-Ah amino acids which are part of the primary and secondary
interface with Ml-iLys are marked with red and yellow dots, respectively. The alignment was created
using STRAP (Gille & Fro¨mmel, 2001).
Table 2
Hydrogen bonds (H) and salt bridges (SB) made by the PliI loops
(primary interface).
PliI-Ah atom Bond type Ml-iLys atom
Loop 2
Ala45 O H Asp47 O1
Ser46 O H Asp47 O2
Ser46 O H Tyr72 O
Loop 4
Asp76 O2 SB Lys102 N
Loop 6
Glu100 O"1 H Ser32 O
Ser101 O H Lys41 N
Ser104 O H Glu18 O"2
Ser104 O H Asn94 N"2
Ser104 N H His93 O
Gly105 N H Asn94 O
Ser106 O H Lys41 N
Tyr107 O H Asn94 O1
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Leysen et al., 2011) can be aligned with the PliI-Ah molecules
in the complex with a C r.m.s.d. of 0.6 A˚ over 118 residue
pairs. At the same time, there is a pronounced local confor-
mation change in the lysozyme near its active site caused by
insertion of loop 6 of the inhibitor. The
-hairpin holding the catalytic residue
Asp29 of the lysozyme is pushed
outwards, resulting in a 4.5 A˚ movement
of its C position compared with the
substrate-bound state (Supplementary
Fig. S2).
The secondary interface between the
PliI-Ah dimer and each bound lysozyme
molecule involves loop 3 of the inhibitor
(Fig. 1a and Supplementary Fig. S3).
Here, PliI-Ah residue Asp65 makes a
salt bridge with Arg75 of the lysozyme,
PliI-Ah residue Asn66 is hydrogen-
bonded to the main-chain carboxyl of
Ml-iLys Trp79, and PliI-Ah residue
Ala68 packs against the aromatic group
of the same residue. Comparison with
other PliI species (Fig. 2) shows that the
sequences of loop 2, loop 4 and espe-
cially loop 6 (all contributing to the
primary interface) are quite conserved.
In contrast, the sequence of loop 3 is
not conserved. At the same time, the
secondary interface still contributes
about 25% of the total interface area
and its role should be further investi-
gated.
3.3. Mutagenesis studies of the
interaction interface
We have shown previously that
replacing Ser104 and Tyr107 by alanines
within the conserved sequence motif
SGxY in loop 6 severely reduces both
the inhibitory activity and the binding
strength of PliI-Ah for Vp-iLys (Leysen
et al., 2011). The crystal structure of
the Ml-iLys–PliI-Ah complex readily
reveals the exact roles of these residues
in the inhibitory mechanism: Ser104
forms a hydrogen bond to the catalytic
Glu18 of Ml-iLys, while both Ser104 and
Tyr107 make hydrogen bonds to Asn94
of the lysozyme (Fig. 1c and Table 2).
The latter residue is part of substrate-
binding site D.
As mentioned above, PliI-Ah loop 2
and loop 4 also take part in blocking
the substrate-binding site. A multiple
sequence alignment (Fig. 2) shows that
Ser46 in loop 2 and Asp76 in loop 4 are
highly conserved across the PliI family.
In parallel with this, these residues are
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Figure 3
Comparison of the inhibitory complexes formed by the MliC/PliC, PliG, Ivy and PliI families. The
inhibitors are shown in cyan as a cartoon with the inserting ‘key’ element in red or as a surface
representation. Their target lysozymes are shown in green as surfaces or as cartoons with the
inserting ‘key’ in yellow. (a) The crystal structure of P. aeruginosa MliC in complex with HEWL
(PDB entry 3f6z; Yum et al., 2009). For clarity, only one chain of the dimeric inhibitor, together with
the bound lysozyme, is shown. The two 180 rotated views show the first and second key–lock
interfaces. (b) The crystal structure of Ec-PliG in complex with salmon g-type lysozyme (PDB entry
4g9s; Leysen et al., 2013). This inhibitor is monomeric. The two views show the first and second key–
lock interfaces. (c) The crystal structure of the Ivy-Ec–HEWL complex (PDB entry 1gpq; Abergel et
al., 2007). Only one chain of the dimeric inhibitor, together with the bound lysozyme, is shown,
revealing a single key–lock interface. (d) The single key–lock pair of the PliI-Ah–Ml-iLys complex.
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found in the PliI-Ah–Ml-iLys interface: Ser46 makes a
hydrogen bond to residue Tyr72 in the lysozyme, while Asp76
makes a salt bridge with the lysozyme residue Lys102 (Fig. 1d).
We have further investigated the functional importance of
Ser46 and Asp76 by creating corresponding alanine mutants
of PliI-Ah and performing a cell-lysis assay in which their
influence on the activity of Vp-iLys was compared with that of
wild-type PliI-Ah. The single amino-acid replacements S46A
and D76A retained 49  6% and 41  6% of the specific
inhibitory activity of the wild type, respectively. Moreover,
when these amino-acid substitutions were introduced, either
individually or together, on top of the S104A/Y107A double
mutation, the inhibitory activity was no longer detectable. This
may be compared with the earlier observations that each of
the single S104A and Y107A mutations does not influence
the activity of PliI-Ah significantly, while the S104A/Y107A
double mutant retains only 15  3% of the wild-type activity
(Leysen et al., 2011). These results indicate that the conserved
residues Ser46, Asp76, Ser104 and Tyr107 located in the
protruding PliI loops all contribute to formation of the inhi-
bitory complex. At the same time, a stable complex can still be
formed even if one of these interactions is missing.
3.4. Comparative mechanism of action of i-type, c-type and
g-type inhibitors on their target lysozymes
Here, we describe the molecular detail of i-type lysozyme
inhibition by the PliI family. Previously, the interactions of
both the MliC/PliC inhibitor family with their target c-type
lysozymes and of the PliG family with the g-type lysozymes
have been shown to involve a ‘double key–lock’ interface
(Leysen et al., 2013; Um et al., 2013; Yum et al., 2009). The first
key–lock pair corresponds to a loop/strand insertion (MliC/
PliC; Fig. 3a) or loop/helix insertion (PliG; Fig. 3b) of the
inhibitor into the active groove of the lysozyme. The second
key–lock pair in either case is formed by a loop of the lyso-
zyme inserting into a pocket on the surface of the inhibitor. In
contrast, the interaction of the Ivy inhibitor with the c-type
lysozyme involves a simpler, single key–lock mechanism, with
a single loop of Ivy inserting into the active site of the lyso-
zyme (Fig. 3c; Abergel et al., 2007). Our new results indicate
that the PliI inhibition also involves a single key–lock pair, but
the ‘key’ inserting into the substrate groove of the lysozyme is
formed by three different PliI loops (Fig. 3d). The largest of
these loops (loop 6) contains the conserved SGxY motif.
Together, the three loops form a ‘ridge’ which complements
the extended shape of the substrate groove. Finally, our
mutagenesis studies reveal that the PliI–iLys interaction is
sufficiently strong to tolerate mutations in single key residues,
but mutations of several residues typically result in both
diminished strength of the interaction and loss of inhibitory
efficiency. Parallel observations have previously been made
for the PliG–gLys pair (Leysen et al., 2012).
3.5. Suppressing lysozyme inhibitors as a novel antibacterial
strategy
The important contribution of specific inhibitors of host
lysozymes to bacterial proliferation has been supported by a
number of findings, as recently reviewed in Callewaert et al.
(2012). In particular, the contribution of lysozyme inhibitors
to the virulence of avian pathogenic E. coli (APEC) was
investigated in an in vivo study. It was shown that expression
of MliC is required for the full virulence of APEC when
injected into one-day-old chickens (Vanderkelen et al., 2012).
Correspondingly, lysozyme inhibitors may serve as targets for
the development of novel antibacterial agents. The accumu-
lated crystal structures of lysozyme–inhibitor complexes of
several types (Fig. 3) provide a starting point for the rational
design of such suppressor molecules. In particular, the ‘lock’
elements on the surface of the MliC/PliC and PliG inhibitors
correspond to ‘druggable’ pockets. The first ‘proof-of-concept’
study in this direction was presented by Voet et al. (2011).
Based on the crystal structure of P. aeruginosa MliC (MliC-
Pa) in complex with hen egg-white lysozyme (HEWL), these
authors identified small molecules capable of disrupting the
interaction between HEWL and PliC from Salmonella enterica
serovar Typhi. For PliI and Ivy inhibitors, however, designing
small suppressor compounds would be problematic owing to
the lack of the second key–lock interface and thus of a suitable
pocket at the inhibitor side. Here, suppression of the inhibi-
tory action might be achieved via the development of anti-
bodies or nanobodies targeting appropriate locations on PliI
or Ivy.
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